Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

Diranersen

Source date not recordedAnalyse record ↗

Tau-lowering antisense oligonucleotide in Phase 2 follow-up for early Alzheimer's disease, with later-stage development planned.

Modality
intrathecal antisense oligonucleotide targeting MAPT mRNA
Availability (US)
Phase 2 CELIA study Active, not recruiting; Biogen states registrational development is planned
Biomarkers
CSF total tau; tau PET; Clinical Dementia Rating-Sum of Boxes; treatment-emergent adverse events
Hallmark targeted
loss of proteostasis, tau accumulation, neurodegeneration
Kind
investigational antisense oligonucleotide
Clinical trials
NCT05399888 — Phase 2, Active, not recruiting on June 30, 2026 registry update